ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2019
Targeting biosynthetic networks of the proinflammatory and proresolving lipid metabolome.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 144 citations in OpenAlex.
- SynbioticNutrients · 2024Trial
- Biosynthesis and analytics of specialized pro-resolving mediators: facts and faults.Journal of lipid research · 2026Review
- Tocotrienol metabolites redirect lipid mediator production in innate immune cells towards inflammation resolution.Acta pharmaceutica Sinica. B · 2026Article
- Reorganization of Innate Immune Cell Lipid Profiles by Bioinspired Meroterpenoids to Limit Inflammation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Microglial 5-LOX-activating protein antagonism alleviates leukotriene-driven neuroinflammation.Acta neuropathologica · 2026Article
- Validated bioanalysis of oxylipins confirms specialized pro-resolving mediator formation in vitro and in vivo.Journal of lipid research · 2026Article
- Encapsulation of the novel mPGES-1 inhibitor TG554 in acetalated dextran nanoparticles.RSC advances · 2026Article
- Social isolation of aged mice drives dramatic release of inflammatory lipoxygenase-derived oxylipins.npj aging · 2026Article
- Accumulation of Siglec10European journal of immunology · 2026Article
- Integrated Analysis of Gut Microbiota and Metabolome Profiling Reveals the Effects of Feeding Approaches on Infants' Gut Microenvironment.Food science & nutrition · 2026Article
- Anti-Inflammatory Lindolin Alkaloids Repress the Transcription of the Microsomal Prostaglandin EJournal of natural products · 2026Article
- Nbeal2 Inactivation Triggers Abl1 Stabilisation and Dysregulated Subcellular Localisation of the Multi-Drug-Resistant Protein MDR1 (ABCB1) in Mast Cells.Immunology · 2026Article
- Unveiling the molecular dynamics of a nitrile-containing 5-lipoxygenase-activating protein antagonist in primary macrophages through Raman spectroscopy.Chemical science · 2026Article
- Rapid adaptive evolution of oxylipin-based chemical defense against algicidal bacteria in a bloom-forming diatom.The ISME journal · 2026Article
- Superior inflammatory response and MASH progression inFrontiers in immunology · 2026Article
- A novelFrontiers in immunology · 2026Article
- Enhanced Efficiency of the Microsomal Prostaglandin EMolecular pharmaceutics · 2025Article
- Human CD24+CD38+ regulatory B cells promote pro-resolving macrophage function through the synergistic effect of IL-10 and PD-L1.Journal of leukocyte biology · 2025Article
- High-fat diet impairs microbial metabolite production and aggravates influenza A infection.Cell communication and signaling : CCS · 2025Article
- Host albumin redirects Candida albicans metabolism to engage an alternative pathogenicity pathway.Nature communications · 2025Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 3 countries.
Funding
Abstract
Nonsteroidal anti-inflammatory drugs interfere with the metabolism of arachidonic acid to proinflammatory prostaglandins and leukotrienes by targeting cyclooxygenases (COXs), 5-lipoxygenase (LOX), or the 5-LOX-activating protein (FLAP). These and related enzymes act in conjunction with marked crosstalk within a complex lipid mediator (LM) network where also specialized proresolving LMs (SPMs) are formed. Here, we present how prominent LM pathways can be differentially modulated in human proinflammatory M1 and proresolving M2 macrophage phenotypes that, upon exposure to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.